U-Neuron Biomedical (ROCO:6973) Other Stockholders Equity: NT$-33.51 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6973 U-Neuron Biomedical Inc ROCO:6973
12 GF Score
Price NT$36.40
! 2 Warning Signs
View Full Analysis

What is U-Neuron Biomedical Other Stockholders Equity?

U-Neuron Biomedical ROCO:6973 +0.69% 12 Other Stockholders Equity is NT$-33.51 Mil as of Dec. 2025. GuruFocus rates ROCO:6973 with a GF Score™ of 12/100. The stock has 2 warning signs investors should review.

U-Neuron Biomedical's Other Stockholders Equity for the quarter that ended in Dec. 2025 was NT$-33.51 Mil.

U-Neuron Biomedical's quarterly Other Stockholders Equity declined from Dec. 2024 (NT$-3.37 Mil) to Jun. 2025 (NT$-8.61 Mil) and declined from Jun. 2025 (NT$-8.61 Mil) to Dec. 2025 (NT$-33.51 Mil).

U-Neuron Biomedical's annual Other Stockholders Equity declined from Dec. 2023 (NT$-1.50 Mil) to Dec. 2024 (NT$-3.37 Mil) and declined from Dec. 2024 (NT$-3.37 Mil) to Dec. 2025 (NT$-33.51 Mil).

U-Neuron Biomedical Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for U-Neuron Biomedical's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

U-Neuron Biomedical Other Stockholders Equity Chart

U-Neuron Biomedical Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial 0.00 -0.00 -1.50 -3.37 -33.51

U-Neuron Biomedical Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.50 -1.50 -3.37 -8.61 -33.51
ROCO:6973
12GF Score
U-Neuron Biomedical Inc ROCO:6973
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

U-Neuron Biomedical Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of NT$-33.51 Mil mean?
U-Neuron Biomedical (ROCO:6973) has a Other Stockholders Equity of NT$-33.51 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on U-Neuron Biomedical and its competitors.
Is U-Neuron Biomedical's Other Stockholders Equity too high?
U-Neuron Biomedical's current Other Stockholders Equity is NT$-33.51 Mil. Overall, U-Neuron Biomedical has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does U-Neuron Biomedical's Other Stockholders Equity compare to VRTX and REGN?
U-Neuron Biomedical's Other Stockholders Equity of NT$-33.51 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on U-Neuron Biomedical and its competitors. U-Neuron Biomedical's current Other Stockholders Equity is NT$-33.51 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is U-Neuron Biomedical stock overvalued right now?
U-Neuron Biomedical (ROCO:6973) has a current Other Stockholders Equity of NT$-33.51 Mil. The current Other Stockholders Equity is NT$-33.51 Mil. U-Neuron Biomedical's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For U-Neuron Biomedical (ROCO:6973), the current Other Stockholders Equity is NT$-33.51 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

U-Neuron Biomedical Business Description

Address Xintai 5th Road, 18th Floor-5, No. 99, Section. 1, Xizhi District, New Taipei City, TWN, 22175
U-Neuron Biomedical Inc is engaged in research and development of stem cell storage & separation technology, and treatment application technology. It has patent on the Technology of Culture and Isolation of Amniotic Fluid Stem Cell.
12GF Score

Get the complete analysis for ROCO:6973

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$36.40
Price